CPT code 0390U designates a Proprietary Laboratory Analyses (PLA) test — PEPredictDx, OncoOmicsDx Laboratory from mProbe — that measures three serum biomarkers by immunoassay and reports a risk score for preeclampsia as early as 11 weeks of pregnancy. As a PLA code, 0390U applies to a single manufacturer-specific laboratory test and is used to identify and track utilization and payment for this proprietary assay at the national level. The code matters for payers and providers because it informs coverage policy, claims processing, and the emergence of biomarker-based prenatal risk assessment.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service settings, and the implications of using a PLA-designated CPT code. The publication summarizes payer coverage considerations, common modifiers reported with laboratory services, and the national policy context for proprietary prenatal diagnostics. It also outlines what stakeholders should expect in terms of billing and documentation practices and highlights areas where data are not available in the input. This national-focused summary provides clinicians, billing professionals, and policy analysts with a clear, high-level brief on 0390U and its role in prenatal care pathways.